In Brief: Genentech hGH patent suit
Genentech hGH patent suit: D.C. federal appeals court grants interim stay of a lower court's preliminary injunction barring Novo from marketing its human growth hormone product Norditropin. The Dec. 17 court order is a reversal of its Aug. 1 order denying Novo's motion for a stay. Genentech says it still expects to have a full patent infringement trial for a permanent injunction ("The Pink Sheet" April 15, T&G-3)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth